The Latest on Multiple Sclerosis and COVID-19 Vaccines The Latest on Multiple Sclerosis and COVID-19 Vaccines
Dr Stephen Krieger on how effective vaccines are in these patients, who should receive boosters, and when.Medscape Neurology
Discussion: Clinical and radiological findings in these cohort of MS patients confirmed disease re/activation and suggested a temporal association between disease activity and COVID-19 vaccination. The nature of this temporal association, whether causative or incidental, remains to be established.
Vaccine administration may be involved in the development of some central nervous system demyelinating diseases. The COVID-19 vaccine is being administered to the entire population, but to date, little association between vaccination and the risk of developing multiple sclerosis (MS) has been suggested, and only a few case reports have been published. Here, we present a 40-year-old woman who developed cervical myelitis after receiving the COVID-19 vaccine. Myelitis was considered the initial clinical manifestation of MS.
AbstractMultiple Sclerosis (MS) has long been considered a T-cell-mediated autoimmune disease of the central nervous system. However, newer evidence shows that B cells play a crucial role in the pathogenesis of MS via antibody production, antigen presentation, T cell stimulation and activation, and production of pro-inflammatory cytokines. Developing B cells express the CD20 molecule from the pre-B cell to the plasmablast stage, and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab and ublituximab are either in use or are being developed for treatment of MS as B cell-depleting therapies. They have show...
Condition: PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial Assay Interventions: Biological: Homologous booster; Biological: Heterologous booster Sponsors: Griffin Hospital; Yale-Griffin Prevention Research Center Not yet recruiting
Since early December 2019, the Coronavirus Disease 19 (COVID-19), the disease caused by the virus Sars-Cov-2, has devastated communities on a global scale, infected over 200 million people, and caused over 4.3 million deaths worldwide . In December 2020, the FDA approved two mRNA vaccines for Sars-Cov-2. After tiresome effort by healthcare workers around the world, over 4.7 billion doses of the vaccine have been administered as of August 2021 .
The statement concludes that COVID-19 vaccines are safe for patients with multiple sclerosis and that most MS patients gain the same protection as the general population. But there are exceptions.Medscape Medical News
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vacci...
Condition: Multiple Sclerosis Intervention: Biological: COVID-19 vaccination Sponsors: Sheba Medical Center; Sanofi Recruiting